C4 Therapeutics (CCCC) Fundamental Analysis: Revenue, Earnings & Valuation

3.18 / 10

Netural

Fundamental score 3.18/10, neutral rating. PB‑ROE and cash‑to‑market are relatively strong, while asset‑to‑market and fixed‑asset turnover are weak. Overall fundamentals are challenging, indicating limited upside.

Analysis Checks(6/10)

Revenue-MV

Value-0.87

Score1/3

Weight12.19%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value1.02

Score3/3

Weight3.15%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.17%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.69%

1M Return1.69%

PB-ROE

Value-0.69

Score2/3

Weight15.30%

1M Return6.97%

Income tax / Total profit (%)

Value-0.12

Score1/3

Weight-0.93%

1M Return-0.50%

Fixed assets turnover ratio

Value0.66

Score1/3

Weight-2.25%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.35%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight28.99%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight14.36%

1M Return5.94%

Is CCCC undervalued or overvalued?

CCCC scores 3.18/10 on fundamentals and holds a Fair valuation at present. Backed by its -44.44% ROE, -292.08% net margin, -2.51 P/E ratio, 1.03 P/B ratio, and 16.45% earnings growth, these metrics solidify its Netural investment rating.